Department of Ophthalmology, Tuzla State Hospital, Istanbul, Turkey.
Department of Medical Pharmacology, Marmara University School of Medicine, Istanbul, Turkey.
Cutan Ocul Toxicol. 2022 Dec;41(4):310-317. doi: 10.1080/15569527.2022.2136193. Epub 2022 Oct 29.
To evaluate the efficacy and safety of topical dexamethasone (DEX) eye drops in combination with a single perioperative subtenon triamcinolone acetonide (sTA) injection versus conventional topical DEX eye drops in the prevention of ocular inflammation and cystoid macular edema following cataract surgery.
Medical records of 245 eyes of 245 patients who underwent uncomplicated cataract surgery were analyzed in this retrospective controlled clinical study. Topical DEX eye drops were administered to 128 eyes routinely postoperatively, and 117 eyes were given a single dose of sTA (40 mg/ml) together with topical DEX eye drops for postoperative care. Postoperative topical antibiotic prophylaxis was applied to all eyes. The primary outcomes were anterior chamber (AC) cells and flare, central macular thickness (CMT), best corrected visual acuity (BCVA), and intraocular pressure (IOP) measurements on day 7, day 30, day 90, and day 180 following surgery.
Although CMT increased in the DEX group, no increment was observed in the DEX + sTA treated group for all follow-up periods (on day 7 (+1.3 ± 18.6 and -8.7 ± 21.9 μm, = 0.038), on day 30 (+20.5 ± 58.4 and -4.1 ± 25.2 μm, = 0.009), on day 90 (+7.2 ± 19.9 and -5.7 ± 30.6 μm, = 0.029), and on day 180 (+8.2 ± 22.6 and -6.4 ± 32.9 μm, = 0.032)). There was no significant difference in terms of AC cells and flare between the two groups during the entire follow-up period ( > 0.05). Significant improvement in BCVA was observed in the DEX + sTA group at day 30 ( = 0.008). IOP differences were comparable, and both groups had high ocular tolerance. There were no severe adverse effects recorded.
Topical DEX eye drops in combination with single dose perioperative injection of sTA have robust efficacy in preventing ocular inflammation and the development of cystoid macular edema following uncomplicated cataract surgery.
评估局部地塞米松(DEX)滴眼液联合单次术周曲安奈德(sTA)注射与常规局部 DEX 滴眼液预防白内障手术后眼内炎症和囊样黄斑水肿的疗效和安全性。
本回顾性对照临床研究分析了 245 例 245 只眼的病历。术后常规给予 128 只眼局部 DEX 滴眼液,117 只眼局部 DEX 滴眼液联合单次 sTA(40mg/ml)治疗。所有眼均行术后局部抗生素预防。主要结局为术后第 7、30、90 和 180 天的前房细胞和房水闪辉、中央黄斑厚度(CMT)、最佳矫正视力(BCVA)和眼压(IOP)测量值。
尽管 DEX 组 CMT 增加,但 DEX+sTA 治疗组在所有随访期间均未观察到增量(术后第 7 天(+1.3±18.6 和-8.7±21.9μm, = 0.038),术后第 30 天(+20.5±58.4 和-4.1±25.2μm, = 0.009),术后第 90 天(+7.2±19.9 和-5.7±30.6μm, = 0.029),术后第 180 天(+8.2±22.6 和-6.4±32.9μm, = 0.032))。在整个随访期间,两组间前房细胞和房水闪辉无显著差异( > 0.05)。DEX+sTA 组术后第 30 天 BCVA 显著改善( = 0.008)。IOP 差异无统计学意义,两组均具有良好的眼内耐受性。无严重不良反应记录。
局部 DEX 滴眼液联合单次术周 sTA 注射对预防单纯白内障手术后眼内炎症和囊样黄斑水肿具有显著疗效。